PT  - JOURNAL ARTICLE
AU  - HIROKI KATAYAMA
AU  - TETSURO TOMINAGA
AU  - TAKASHI NONAKA
AU  - MASATO ARAKI
AU  - YORIHISA SUMIDA
AU  - HIROAKI TAKESHITA
AU  - HIDETOSHI FUKUOKA
AU  - KAZUO TO
AU  - KENJI TANAKA
AU  - TERUMITSU SAWAI
AU  - TAKESHI NAGAYASU
TI  - Effect of Neoadjuvant Chemotherapy in Patients With Locally Advanced Rectal Cancer: A Multicenter Propensity Score-matched Analysis
AID  - 10.21873/anticanres.15625
DP  - 2022 Mar 01
TA  - Anticancer Research
PG  - 1527--1533
VI  - 42
IP  - 3
4099  - http://ar.iiarjournals.org/content/42/3/1527.short
4100  - http://ar.iiarjournals.org/content/42/3/1527.full
SO  - Anticancer Res2022 Mar 01; 42
AB  - Background/Aim: The effect of neoadjuvant chemotherapy (NAC) and adjuvant chemotherapy (AC) for locally advanced rectal cancer (LARC) is not fully understood. This study aimed to identify outcomes following NAC plus AC for LARC. Patients and Methods: We reviewed 252 patients who underwent curative resection for LARC. Propensity score matching matched 51 patients in NAC and non-NAC groups. Results: Operative time (443 min vs. 286 min, p<0.001), blood loss (279 ml vs. 124 ml p<0.001), and number of patients who received AC were higher in the NAC group (74.5% vs. 33.3%, p<0.001). The Disease control rate of NAC group was 98.1%. The NAC group showed better 3-year RFS (86.5% vs. 62.1%, p=0.021). Patients who received both NAC and AC displayed better 3-year RFS (90.2%) compared to the non-NAC group both with (63.8%) and without (60.4%) AC (p<0.05). Conclusion: NAC and AC for LARC have the potential to improve oncological outcomes.